Israeli biotech company KAHR rakes in $12 mln Series B
Israeli biotech company KAHR Medical Ltd has secured $12 million in Series B funding. The investors in this round were Korea Investment Partners, Mirae Asset Venture Investment, DSC Investment and return backer Flerie Invest AB. RM Global Partners advised KAHR on the transaction.
15 December 2015•4 mins read
